Skip to contentI
Intelligent Bio Solutions Inc.
I
INBSIntelligent Bio Solutions Inc. Q3 2026 · 10-Q
Revenue$1.06M$1.06M+45.5% vs Q3 2025 Net Income-$2.86M-$2.86MN/M vs Q3 2025 EPS Diluted-$1.80-$1.80N/M vs Q3 2025 Gross Profit$535,381+56.8% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Intelligent Bio Solutions Inc. · CIK 1725430 · Engraved from SEC EDGAR
Operating Cash Flowderived-$4,330,574N/M Free Cash Flowderived-$4,317,672— Margins · derivedGross margin50.5%+3.6 pt vs Q3 2025
Operating margin-277.8%+73.5 pt vs Q3 2025
Net margin-269.9%+79.1 pt vs Q3 2025
ended Mar 31, 2026 · filed May 13, 2026 · 43 d after period end